TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage company focused on RNA therapeutics for cancer, announced the appointment of Anna Moore, PhD, as Chair of its Scientific Advisory Board and the execution of a sponsored research agreement with Michigan State University. The collaboration aims to advance the company's lead candidate, TTX-MC138, including evaluation in combination with other therapies. Dr. Moore will provide strategic guidance on research and development efforts targeting advanced cancers.
The appointment of Dr. Moore, a renowned expert in molecular imaging and nanomedicine, is expected to bolster TransCode's scientific leadership. Dr. Moore currently serves as Director of the Precision Health Program and a professor in the Department of Radiology at Michigan State University. Her research focuses on developing imaging and therapeutic agents for cancer, which aligns with TransCode's mission to treat metastatic tumors.
TransCode's lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis. The sponsored research agreement with Michigan State University will support preclinical studies, potentially evaluating TTX-MC138 in combination with other therapies. This partnership could accelerate the development of new treatment options for patients with advanced cancers.
The company's pipeline includes other first-in-class therapeutic candidates designed to mobilize the immune system against cancer cells. TransCode's approach leverages RNA-based platforms to address high-risk and advanced cancers, areas of significant unmet medical need. The research agreement and advisory board appointment underscore the company's commitment to advancing its pipeline through academic collaborations.
For more information, see the full press release here. Investors can find the latest news and updates regarding RNAZ in the company's newsroom here.
